利多卡因丙胺卡因气雾剂

Companies, stages and changes, with each record available on this page.

Current coverage may be incomplete

Complete CDE snapshot: 2026/11/10 07:27
Matching scope: Same generic name; dosage forms and combinations kept separate
Coverage: Source dates and limits ↓

Which companies are listed, and at what stages?

Each source is counted separately. Expand a list to inspect companies, identifiers, dates and sources.

Company names, approval identifiers and strengths are retained as recorded in the Chinese sources. Category labels include the original wording for verification.

Catalogue holders0View records ↓ Under-review filings5View records ↓ This year’s generic filers4View records ↓ NHSA approval numbers0View records ↓ API companies with A status0View records ↓

Chemical-drug catalogue

Loaded records: 0 holders; 0 in the quality-and-efficacy consistency-evaluation category, and 0 in the new chemical-registration-classification generic category. Category counts may overlap.

Marketing authorization holder	Manufacturer	Approval number	Approved	Strength / specification	Catalogue category (source text)	View source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Distinct full holder names; manufacturers are used only where the holder is unstated. The catalogue covers only part of the chemical-drug market. Categories are counted as recorded, not as a complete market census.

NHSA drug codes

Loaded records: 0 distinct approval numbers and 0 companies.

Company / applicant	Approval number	Strength / specification	NHSA class	NHSA drug code	View source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Approval numbers and companies are deduplicated separately; packaging records remain individually listed. An empty insurance class means it is unstated. NHSA codes supply no approval date and do not establish the outcome of an acceptance number.

Current under-review applications

Loaded records: 5 filings and 5 distinct first applicants.

Generic 5

Current under-review applications
Company / applicant	Acceptance number	Application type	Accepted	Strength / specification	View source
广州白云山医药集团股份有限公司白云山制药总厂;扬州市三药制药有限公司	CYHS2602421	Generic	2026/09/29	Not stated by source	CDE
江苏柯菲平医药股份有限公司;北京京丰制药集团有限公司	CYHS2504465	Generic	2025/12/30	Not stated by source	CDE
福元药业有限公司	CYHS2602321	Generic	2026/09/17	Not stated by source	CDE
上海上药信谊药厂有限公司	CYHS2600999	Generic	2026/04/29	Not stated by source	CDE
山东华铂凯盛生物科技有限公司;鲁南贝特制药有限公司	CYHS2600308	Generic	2026/01/29	Not stated by source	CDE

New generic filings in 2026

Loaded records: 4 filings and 4 distinct first applicants.

New generic filings in 2026
Company / applicant	Acceptance number	Application type	Accepted	Strength / specification	View source
广州白云山医药集团股份有限公司白云山制药总厂;扬州市三药制药有限公司	CYHS2602421	Generic	2026/09/29	Not stated by source	CDE
福元药业有限公司	CYHS2602321	Generic	2026/09/17	Not stated by source	CDE
上海上药信谊药厂有限公司	CYHS2600999	Generic	2026/04/29	Not stated by source	CDE
山东华铂凯盛生物科技有限公司;鲁南贝特制药有限公司	CYHS2600308	Generic	2026/01/29	Not stated by source	CDE

API registrations

Non-component matches: 0 companies with A status and 0 I-status records. Component matches are listed separately and excluded from these counts.

Name	Company / applicant	Registration number	Status	Name match	Source update date	View source
No matching records were found in the currently loaded source data; coverage dates are listed below.

A/I are source statuses. Matching uses exact ingredients, salt-normalized names and maintained combination components, without fuzzy matching. A-status companies are deduplicated by the first registered company. Components are excluded from headline counts; the register does not identify the associated formulation.

What changed recently?

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately.

Trial registration does not mean an application will follow.

This product is outside the trial-registration backfill scope. New registrations after daily collection started remain in scope. Historical rows may also be found by another product search; neither implies complete historical coverage for this product.

NHSA edition maintained to 2026-10-23; latest successful catalogue check: 2026/11/10 07:23. NHSA records lack approval dates; only an earlier edition or observation establishes precedence.

2026/09/29Accepted

广州白云山医药集团股份有限公司白云山制药总厂;扬州市三药制药有限公司
CYHS2602421

Fact date: 2026/09/29 · Site observation date: 2026/10/21
View source ↗
2026/09/17Accepted

福元药业有限公司
CYHS2602321

Fact date: 2026/09/17 · Site observation date: 2026/10/22
View source ↗

How current is each source?

CDE acceptances and review

Last successful update: 2026/11/10 07:27

Chemical-drug catalogue

Last successful update: 2026/11/10 07:23

Full API register

Last successful update: 2026/11/10 07:25

NHSA drug codes

Last successful update: 2026/11/05 06:45

The fully loaded edition was maintained to 2026-10-23. Publication lags maintenance: the verified 2026-10-16 edition was published on 10-28, a 12-day gap. This is not a fixed lag for every edition.

NMPA drug delivery notices

Last successful update: 2026/11/10 18:31

First index-page publication dates: 2026-10-26 to 2026-11-10; 0 pages pending. Covers loaded notices only, not a complete historical approval database.

Drug Clinical Trial Registry and Information Disclosure Platform

Last successful update: 2026/11/10 08:10 · Current coverage may be incomplete

Daily collection reads new registrations. Backfill covers registration numbers from 2025 onward (CTR2025/CTR2026), not first-publication years. States are dated observations; revisions are not tracked.

Public-product searches scanned: 3/30; discovered pending details: 20. Record counts in unscanned portions remain unknown.

Filings are counted by acceptance number and filing companies by first applicant. Strengths may have separate applications. Drug names are normalized only for width and whitespace; distinct generic names, dosage forms and combinations remain separate. Unstated strengths are marked. Company counts from different sources must not be added together.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

About the Chinese official sources

Each source counts a different type of public record. Coverage dates and gaps are listed separately above.

CDE — The Center for Drug Evaluation lists application acceptances and applications currently under review.
CDE catalogue — The chemical-drug catalogue lists approvals, marketing authorisation holders and the original inclusion categories.
NHSA — The National Healthcare Security Administration maintains medicine codes, companies and approval numbers; its database is not an application decision register.
NMPA — The National Medical Products Administration publishes delivery notices for approval documents and notifications. Loaded notices do not cover all historical approvals.
CDE API registry — The active pharmaceutical ingredient registry lists registrations and their A/I association-review status.
Drug Clinical Trial Registry — Public registration numbers, applicants, first-publication dates and original classifications/phases. States are dated site observations; revisions are not continuously tracked.

Free follow

Follow changes to this drug

Up to 3 drugs per email address, in one weekly digest. Starts after email confirmation; unsubscribe at any time.

Subscriptions

Next-day facts and deliverable timelines

One email the next day when new facts are collected for your followed products.
Export the complete loaded event timeline for each followed product as CSV.
Add up to 4 additional recipients, each confirmed by email.
Increase your follow limit from 3 to 10 products.

Monthly

US$200

Billed every month

Quarterly

US$540

Billed every three months

US$180 per month

Yearly

US$1,920

Billed every year

US$160 per month

Online subscriptions are not enabled. The form below registers interest; it does not charge or activate access.

Separate one-time purchase

US Orange Book × China records comparison

Full table and CSV export for 12 months from payment, with monthly data updates. No automatic renewal.

Subscriptions and comparison-table access are purchased separately. Neither includes the other.

US$490

One payment · 12 months of access

Online comparison-table purchase is not enabled.

Billed by Creem, our merchant of record · Terms · Refund policy